Chronic Urticaria Clinical Trial
Official title:
Quality of Life,Anxity,Depression and Quality of Sleep in Patients With Chronic Urticaria
Urticaria is one of the most frequent presenting complaints in dermatology, allergy, and emergency departments. The term chronic urticaria (CU) is understood as the appearance of recurrent wheals more than twice a week for over 6 consecutive weeks .Urticaria is not a single disease but a reaction pattern that represents cutaneous mast cell degranulation, resulting in extravasation of plasma into the dermis. The incidence of chronic urticaria is unknown, but it is thought to occur in 0.1%-3% of the population
Chronic urticaria signs and symptoms include: patches of red or white wheals, usually on the
face, trunk, arms or legs. Wheals vary in size, change shape, and appear and fade repeatedly
as the reaction runs its course. Itching is common, which may be severe. Swelling may occur
that causes pain or burning (angioedema), especially inside the throat and around the eyes,
cheeks, lips, hands, feet and genitals.
It is characterized by a tendency for signs and symptoms to flare with triggers such as
heat, exercise and stress as well as a tendency for symptoms to recur frequently and
unpredictably, sometimes for months or years The significance of chronic urticaria is
sometimes trivialised because it is a non-life-threatening disease, but the condition can be
very uncomfortable and interfere with sleep and daily activities. It is one of the most
common and frustrating diseases for both patients and physicians Chronic urticaria has a
major impact on quality of life (QoL) , with impact on activities of daily living. Chronic
urticaria patients reportedly suffer considerable loss of energy, sleep disturbance and
emotional upset as well as restrictions in the social life. Depression and anxiety are the
most common psychiatric diagnoses. These psychiatric disorders could also influence QoL
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02435238 -
AWARE - Chronic Urticaria
|
N/A | |
Not yet recruiting |
NCT05513079 -
Positive Psychotherapy-Based Counseling (PPT)
|
N/A | |
Terminated |
NCT02047136 -
Dietary Treatment for Chronic Urticaria
|
N/A | |
Completed |
NCT01803763 -
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT01170949 -
Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria
|
Phase 2 | |
Completed |
NCT00598611 -
Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)
|
Phase 3 | |
Completed |
NCT01610128 -
Development of an Urticaria Control Test
|
N/A | |
Completed |
NCT02285049 -
Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test
|
N/A | |
Completed |
NCT02285023 -
The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
|
||
Completed |
NCT01715740 -
Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria
|
Phase 3 | |
Completed |
NCT01960283 -
Methotrexate in the Treatment of Chronic Idiopathic Urticaria
|
Phase 3 | |
Completed |
NCT00481676 -
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
|
Phase 2 | |
Completed |
NCT01713725 -
Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
|
Phase 2 | |
Completed |
NCT01250652 -
Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses
|
Phase 4 | |
Completed |
NCT01111136 -
Stress Intervention for Chronic Urticaria
|
N/A | |
Recruiting |
NCT01425593 -
T Cell Function in Chronic Idiopathic Urticaria
|
N/A | |
Completed |
NCT00628108 -
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
|
Phase 3 | |
Completed |
NCT00737451 -
Association of Thyroid Autoimmunity and Chronic Urticaria
|
N/A | |
Completed |
NCT00619801 -
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
|
Phase 3 | |
Completed |
NCT01284426 -
Natural History of Chronic Urticaria
|
N/A |